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Since many exogenous substances, including ecotoxi-
cants, pharmaceuticals, food additives, and others are
undergone to metabolic transformations by cytochrome
P450, information about their fate in the human organ-
ism is very important. Comparing to the parent com-
pounds, metabolites produced by biotransformation
reactions may reveal higher toxicity (e.g., having carcino-
genic potency) or may have more potent biological activ-
ity (this property is used in case of prodrugs). Induction or
inhibition of cytochromes P450, which take part in
biotransformation, may lead to decrease or increase of
biological effects of ecotoxicants and drugs. Development
of software for computer prediction of biotransformation
of xenobiotics in the human organism and cytochrome
P450 substrate/inhibition/induction activity for drug-like
compounds was performed on the basis of PASS technol-
ogy http://www.ibmc.msk.ru/PASS/. One created soft-
ware product is designed as a tool for prediction of
biotransformation classes (e.g. "N-Glucuronidation",
"Acylation", "N-Hydroxylation, Cytochrome P450,
CYP3A4" etc.) and substrate/inhibitor/inducer activity
(CYP3A4 inducer, CYP2C9 substrate, CYP2C19 inhibitor
etc.) of drug-like compounds in the human organism.
Training set is used for prediction of biotransformation
spectra for new chemical compounds. Created software
product predicts about 400 kinds of biotransformation
terms with the mean prediction accuracy of about 88%.
For validation and testing of program we used the test set
created on the basis of information presented in "The Top
100 Drug Interaction 2006 H&H Publications". The test
set contains 260 chemical structures of drugs and data
about their substrate/inhibition/induction properties.
Interaction with the CYP2C19, CYP3A4, CYP2D6,
CYP2C9, CYP1A2 isoforms of cytochrome P450 was pre-
dicted. Accuracy of prediction is 74%, sensitivity is 69%,
specificity is 75%. Another software product is designed as
a tool for prediction of C-Hydroxylation sites for drug-like
compounds in the human organism. In current version,
program is able to predict C-Hydroxylation sites for com-
pounds in the human organism with the mean prediction
accuracy of about 90%. If the appropriate training set and
biotransformation fragments will be available, the pro-
gram can be extended to prediction of sites for other
biotransformation. Prediction of C-Hydroxylation
biotransformation sites is realized by using of RMNA
descriptors and metabolite generation procedure. For val-
idation of the program, prediction versus random tests
sets was performed. Two test set contains 130 and 260
structures xenobiotics. Accuracy of C-Hydroxylation pre-
dictions for two test sets and for various levers of RMNA
descriptors is about 70%. Results obtained of C-Hydroxy-
lation predictions and prediction of xenobiotics interac-
tion with the main isoforms of cytochrome P450 look
reasonable to use them for solution of practical tasks of
toxicology and pharmacology.
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